Holen Sie sich die Stockscreener-App
23.85
0.42%
0.10
Handel nachbörslich:
24.42
0.57
+2.39%
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Health stock rises as director buys shares By Investing.com - Investing.com Nigeria
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA - Proactive financial news
HIMS stock extends 3-day rally: Hims & Hers targets GLP-1 gold rush in Canada after Novo Nordisk patent expiry - MSN
Hims & Hers Health, Inc. Stock 12‑Month Price Target Cut to $27.71, Implies 17% Upside - TradingView
Hims & Hers Stock Jumped 6.6% This Week. Here’s What a $350 Million Capital Raise for Growth - TIKR.com
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock - Yahoo Finance Australia
BofA cuts Hims and Hers stock price target on GLP-1 ramp concerns - Investing.com Canada
Modest pullback for Hims & Hers Health stock as oversold signals emerge - Traders Union
$Hims & Hers Health (HIMS.US)$ Should i cut loss now[Sob]im almost enough with this - Moomoo
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Four telehealth platforms now offer generic semaglutide - Benefits and Pensions Monitor
Hims & Hers Health stock price forecast: $22.50 support as HIMS trades down - Traders Union
(HIMS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
How The Hims & Hers Health (HIMS) Story Is Shifting With GLP‑1 Hopes And Margin Questions - Yahoo Finance
Hims & Hers Health (HIMS) Stock Forum and Discussion - Moomoo
HIMS stock slips overnight: Hims & Hers bulks up debt raise to $350M for Eucalyptus buyout, AI push - MSN
Hims & Hers Health Inc. Class A (HIMS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Hims & Hers Health Options Spot-On: On May 22nd, 109.56K Contracts Were Traded, With 1.05 Million Open Interest - Moomoo
Hims & Hers (HIMS) CMO-director gets 435 RSUs instead of $10K cash retainer - Stock Titan
Hims & Hers (HIMS) director Christopher Payne awarded 647 RSUs for Q1 2026 fees - Stock Titan
Hims & Hers Health (HIMS) director awarded 957 RSUs for Q1 fees - Stock Titan
Latham Advises on Hims & Hers Health, Inc.’s Upsized US$350 Million Convertible Senior Notes Offering - Latham & Watkins LLP
HIMS Maintained by Truist Securities -- Price Target Raised to $23 - GuruFocus
Hims & Hers Deepens Personalized Care Through Platform Expansion - TradingView
Hims & Hers Has Fallen 66% From Its Peak. Does the $350M Debt Raise Signal a Turning Point or a Red Flag? - TIKR.com
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating - Moomoo
Truist raises Hims and Hers stock price target on GLP-1 insights - Investing.com
Hims & Hers Health, Inc. Announces Issuance of 0.00% Convertible Senior Notes Due 2032 and Indenture with U.S. Bank Trust Company - Minichart
HIMS News | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry - Yahoo Finance
Hims & Hers Health Inc (HIMS) Stock Up 4.2% and Still Undervalued -- GF Score: 77/100 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers H - The National Law Review
Hims & Hers Health issues $402.5 million in convertible senior notes due 2032 - Investing.com
Hims & Hers Health Raises $402.5 Million Via 0% Convertible Notes; Adds Capped Calls at $50.15 Cap - TradingView
Hims & Hers (NYSE: HIMS) issues $402.5M 2032 zero-coupon convertibles - Stock Titan
Hims & Hers stock gains on Canada GLP-1 launch By Investing.com - Investing.com Nigeria
Hims & Hers stock gains on Canada GLP-1 launch - Investing.com
Canadians can now get digital prescriptions for 'generic Ozempic' - Financial Post
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry - Reuters
The Silver Lining of Last Week's Hims & Hers Earnings Miss - MarketBeat
Is Hims and Hers Health Stock a Buy After Its Latest Dip? - AOL.com
HIMS Launches Generic Semaglutide in Canada - GuruFocus
Why Hims & Hers Health Stock Just Crashed - AOL.com
Hims & Hers launches generics for Novo’s semaglutide in Canada - Seeking Alpha
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide - HIMS Investor Relations
Hims & Hers Introduces Access to Generic Semaglutide for Canadian Customers - Hims & Hers Newsroom
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Business Wire
HIMS Stock Midweek Analysis | Hims & Hers Health, Inc. (HIMS) Stock Forecast (IK4SVsTRUr) - fathomjournal.org
Hims & Hers Health Q1 2026: Strategic Shift to Branded Medications Weighs on Results - IndexBox
Eucalyptus acquisition prospect lifts Hims & Hers Health stock 2.67% higher - Traders Union
HIMS Becomes a Retail Sentiment Standout as Bullish Mentions Rise to 70% - openPR.com
HIMS Stock Chart | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
HIMS Stock Slips Overnight: Hims & Hers Bulks Up Debt Raise To $350M For Eucalyptus Buyout, AI Push - Stocktwits
Live Longer and Better. Does Medicine’s New Obsession Really Work? - Barron's
Hims & Hers Health, Inc. - dailyvoice.com
Hims & Hers stock slips as dilution fears outweigh new capital - MSN
Hims & Hers Stock Slips As Dilution Fears Outweigh New Capital - Benzinga
Hims & Hers: Wegovy Deal Fuels Growth (NYSE:HIMS) - Seeking Alpha
5.02%
5.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):